Every SEC Form 3/4/5 on record for this filer (CIK 1391045) — 7 issuers, 47 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | Director | 2017-01-05 → 2026-02-06 | 16 | −$3M |
| BCYC | BICYCLE THERAPEUTICS PLC | Director | 2019-05-22 → 2025-01-06 | 15 | −$10M |
| UROV | Urovant Sciences Ltd. | Director · lapsed | 2018-09-26 → 2021-03-31 | 6 | — |
| ADYX | Alliqua BioMedical, Inc. | Director · lapsed | 2019-05-07 → 2019-05-07 | 1 | — |
| ARMO | ARMO BioSciences, Inc. | Director · lapsed | 2018-01-25 → 2018-06-22 | 3 | — |
| TBRA | Tobira Therapeutics, Inc. | Director · lapsed | 2015-07-13 → 2016-11-03 | 3 | — |
| NRX | NephroGenex, Inc. | Chief Executive Officer · Director · lapsed | 2015-11-12 → 2015-11-12 | 1 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| SNDX | 2023-01-13 | Sell | 10,000 | $27.00 | $270,000 | 32,000 |
| SNDX | 2023-01-13 | Sell | 5,000 | $27.00 | $135,000 | 32,000 |
2 of 7 issuers are covered and open a security page; the rest are on file here only.
